Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870427 · ClinicalTrials.gov registry record · Phase 4
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
A Phase 4 study, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01870427 is a Phase 4 study that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 20 participants.
The verdict
NCT01870427, a Phase 4 study, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
Interventions
- DRUG Aflibercept (2.0 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870427
The ClinicalTrials.gov registry entry for NCT01870427 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Retina Vitreous Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aflibercept (2.0 mg) is the first listed.
NCT01870427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870427 about?
NCT01870427 is a clinical study titled "NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions". The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
What is the current status of trial NCT01870427?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2013-06. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01870427?
The interventions under investigation include: Aflibercept (2.0 mg) (DRUG).
Who is sponsoring clinical trial NCT01870427?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.